Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Vecta Ltd. |
---|---|
Information provided by: | Vecta Ltd. |
ClinicalTrials.gov Identifier: | NCT00818870 |
The study is designed to assess and compare the effect of Vecam 40/300, Vecam 20/300 and Omeprazole 20 mg (a standard FDA approved GERD treatment) on the control of gastric pH.
Condition | Intervention | Phase |
---|---|---|
Gastroesophageal Reflux |
Drug: Omeprazole Drug: Vecam |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Pharmacodynamics Study |
Official Title: | A Randomized, Open-Label, Cross-Over, Dose-Ranging Study to Assess the Effect of Vecam 40/300 and Vecam 20/300 Administered at Bedtime Compared to Omeprazole 20 mg Administered Before Breakfast on Gastric pH |
Estimated Enrollment: | 60 |
Study Start Date: | December 2008 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Omeprazole 20 mg: Active Comparator |
Drug: Omeprazole
20 mg capsule, orally, once daily (before breakfast) for 5 days.
|
Vecam 20/300: Experimental |
Drug: Vecam
1 capsule, orally, once daily at bedtime for 5 days.
|
Vecam 40/300: Experimental |
Drug: Vecam
1 capsule, orally, once daily at bedtime for 5 days.
|
Eligible H. pylori negative, normal gastric acid secreting, healthy volunteers will be treated by the study medications in a randomized, open-label, cross-over study.Up to 60 volunteers may be enrolled to ensure that at least 30 subjects will complete all the study treatments. Omeprazole 20 mg will be administered before breakfast. Vecam 40/300 and Vecam 20/300 will be administered at bedtime w/o food. 24-hour gastric pH will be measured after the fifth dose (day 5).Following screening procedures, subjects will be randomly assigned to receive the different treatments.
All pH measurements will be done in the study center under supervised conditions. All drug administrations will be supervised.
This study is part of the Vecam clinical development plan.
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Any significant history of / or concurrent gastrointestinal diseases or conditions such as:
Concurrent use of gastric anti-secretory drugs such as defined below:
United States, California | |
Clinical Applications Laboratories Inc. | Recruiting |
San Diego, California, United States, 92103 | |
Contact: Vijayalakshmi S Pratha, MD 619-260-1012 |
Principal Investigator: | Vijayalakshmi S Pratha, MD | Clinical Applications Laboratories Inc. |
Responsible Party: | Vecta ( Richard E. Lowenthal ) |
Study ID Numbers: | VCT006 |
Study First Received: | January 6, 2009 |
Last Updated: | January 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00818870 |
Health Authority: | United States: Food and Drug Administration |
Gastroesophageal Reflux GERD Nocturnal GERD |
Heartburn Nighttime Heartburn Nocturnal Heartburn |
Deglutition Disorders Esophageal Motility Disorders Pyrosis Digestive System Diseases Esophageal disorder |
Gastrointestinal Diseases Heartburn Omeprazole Esophageal Diseases Gastroesophageal Reflux |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Anti-Ulcer Agents |
Gastrointestinal Agents Enzyme Inhibitors Pharmacologic Actions |